Raymond James analyst Jayson Bedford downgraded Tandem Diabetes to Market Perform from Outperform without a price target. The firm expects margins to remain depressed in the near-term as Tandem funds its pipeline, and must see better market growth, share stabilization, and/or pipeline development before regaining more confidence in the story, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes downgraded to Market Perform from Outperform at Raymond James
- Tandem Diabetes down 5% after FDA approves Medtronic’s MiniMed 780G
- Tandem Diabetes Care announces publication of meta-analysis of Control-IQ trials
- Piper wonders if Medtronic’s 780G will be delayed further by FDA inspections
- Tandem Diabetes initiated with a Neutral at UBS